Missed GME or NVDA? Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
PBAX Stock Forecast 2025-2026
$0.89
Current Price
$36.47M
Market Cap
Buy 0
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to PBAX Price Targets
N/A
To High Target of $N/A
N/A
To Median Target of $N/A
N/A
To Low Target of $N/A
PBAX Price Momentum
+39.1%
1 Week Change
+18.7%
1 Month Change
-36.0%
1 Year Change
-85.4%
Year-to-Date Change
-91.3%
From 52W High of $10.25
+1,806.0%
From 52W Low of $0.05
📉 MARKET SELLOFF ALERT
10 Quality Stocks Worth Considering Now
Researching Phoenix Biotech (PBAX) after the drop? Our ex-Goldman Sachs analyst reveals if it made our list of 10 oversold quality stocks with strong growth potential.
Get our FREE market selloff report + exclusive analysis on PBAX and similar high-potential opportunities.
Latest PBAX Stock Price Targets & Analyst Predictions
PBAX has shown a year-to-date change of -85.4% and a 1-year change of -36.0%, reflecting downward momentum over the past year. Comprehensive analyst forecasts are currently unavailable for PBAX. Please refer to the price chart above for recent performance and trends.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
PBAX Analyst Ratings
0
Buy
0
Hold
0
Sell
PBAX Price Target Range
Low
N/A
Average
N/A
High
N/A
Current: $0.89
Latest PBAX Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for PBAX.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|
Phoenix Biotech Acquisition Corp. (PBAX) Competitors
The following stocks are similar to Phoenix Biotech based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Phoenix Biotech Acquisition Corp. (PBAX) Financial Data
Phoenix Biotech Acquisition Corp. has a market capitalization of $36.47M with a P/E ratio of -29.7x. The company generates $0 in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of 0.0% and return on equity of -27.0%.
Valuation Metrics
Market Cap
$36.47M
Enterprise Value
$37.82M
P/E Ratio
-29.7x
PEG Ratio
0.0x
Price/Sales
0.0x
Growth & Margins
Revenue Growth (YoY)
N/A
Gross Margin
N/A
Operating Margin
0.0%
Net Margin
0.0%
EPS Growth
N/A
Financial Health
Cash/Price Ratio
+2.1%
Current Ratio
1.8x
Debt/Equity
-0.3x
ROE
-27.0%
ROA
-2.5%
💰 DON'T MISS THIS OPPORTUNITY
Get All 10 Quality Stocks For This Market Selloff
Still researching investments after the market drop? Our ex-Goldman Sachs analyst has already identified the 10 highest-quality oversold stocks with strong fundamentals and upside potential.
Why spend hours researching when we've already done the work? Get instant access to our complete market selloff analysis.
Phoenix Biotech Acquisition Corp. (PBAX) Business Model
About Phoenix Biotech Acquisition Corp.
What They Do
Focuses on healthcare-related business acquisitions.
Business Model
The company operates as a blank check company, seeking to merge or acquire businesses in the healthcare sector. It generates value by identifying and partnering with promising healthcare companies in the U.S. and Europe, facilitating their growth and expansion.
Additional Information
Incorporated in 2021 and based in Oakland, California, the company does not have significant operations yet, but is positioned to capitalize on opportunities within the healthcare industry.
Company Information
Sector
Financial Services
Industry
Shell Companies
Employees
0
CEO
Mr. Christopher B. Ehrlich M.B.A.
Country
United States
IPO Year
2021
Phoenix Biotech Acquisition Corp. (PBAX) Latest News & Analysis
Latest News
Phoenix Biotech Acquisition Corp. and CERo Therapeutics, Inc. Announce Close of Business Combination
1 year ago
Quick Summary
Phoenix Biotech Acquisition Corp. (PBAX) has completed its business combination with CERo Therapeutics, making CERo a publicly-traded company focused on engineered T cell therapeutics.
Why It Matters
The merger of Phoenix Biotech Acquisition Corp. and CERo Therapeutics creates a new public player in immunotherapy, potentially attracting investment interest and impacting market dynamics in biotech.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
CERo Therapeutics and Phoenix Biotech Acquisition Corp. have announced a definitive business combination agreement, aiming to advance engineered T cell therapeutics.
Why It Matters
The merger between CERo Therapeutics and PBAX could lead to significant advancements in immunotherapy, potentially increasing market interest and valuation for both companies.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
Intrinsic Medicine and Phoenix Biotech Acquisition Corp. have mutually terminated their business combination agreement due to unfavorable market conditions.
Why It Matters
The termination of the business combination between Intrinsic Medicine and Phoenix Biotech indicates potential instability in the biotech sector and could impact investor confidence and stock valuations.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Intrinsic Medicine, Inc. and Phoenix Biotech Acquisition Corp. announced a definitive merger. The new entity will be named Intrinsic Medicine, Inc., trading as “INRX” on Nasdaq post-transaction in H1 2023.
Why It Matters
The merger positions Intrinsic Medicine for growth in the biotech sector, potentially increasing its stock value and market visibility, which can attract investors seeking innovative healthcare opportunities.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About PBAX Stock
What is Phoenix Biotech Acquisition Corp.'s (PBAX) stock forecast for 2025?
Analyst forecasts for Phoenix Biotech Acquisition Corp. (PBAX) are not currently available. The stock is trading at $0.89.
Is PBAX stock a good investment in 2025?
Analyst ratings for PBAX are not currently available. The stock is currently trading at $0.89. Investment decisions should be based on thorough research and your personal financial goals. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for PBAX stock?
Price predictions from Wall Street analysts for PBAX are not currently available. The stock is trading at $0.89.
What is Phoenix Biotech Acquisition Corp.'s business model?
The company operates as a blank check company, seeking to merge or acquire businesses in the healthcare sector. It generates value by identifying and partnering with promising healthcare companies in the U.S. and Europe, facilitating their growth and expansion.
What is the highest forecasted price for PBAX Phoenix Biotech Acquisition Corp.?
Price targets from Wall Street analysts for PBAX are not currently available. The stock is trading at $0.89.
What is the lowest forecasted price for PBAX Phoenix Biotech Acquisition Corp.?
Price targets from Wall Street analysts for PBAX are not currently available. The stock is trading at $0.89.
What is the overall PBAX consensus from analysts for Phoenix Biotech Acquisition Corp.?
Analyst ratings for PBAX are not currently available. The stock is trading at $0.89.
How accurate are PBAX stock price projections?
Stock price projections, including those for Phoenix Biotech Acquisition Corp., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: April 28, 2025 4:43 AM UTC